Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:


Last Updated: September 26, 2022

VUSION Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

When do Vusion patents expire, and when can generic versions of Vusion launch?

Vusion is a drug marketed by Mylan and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in VUSION is miconazole nitrate; white petrolatum; zinc oxide. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the miconazole nitrate; white petrolatum; zinc oxide profile page.

DrugPatentWatch® Generic Entry Outlook for Vusion

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 30, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for VUSION
Drug patent expirations by year for VUSION
Drug Prices for VUSION

See drug prices for VUSION

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VUSION
Generic Entry Date for VUSION*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VUSION

Identify potential brand extensions & 505(b)(2) entrants

Image Dermatology P.C.Early Phase 1
GlaxoSmithKlinePhase 4
Stiefel, a GSK CompanyPhase 4

See all VUSION clinical trials

Pharmacology for VUSION

US Patents and Regulatory Information for VUSION

VUSION is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VUSION is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VUSION

Modified azole compounds as antifungal and antibacterial agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan VUSION miconazole nitrate; white petrolatum; zinc oxide OINTMENT;TOPICAL 021026-001 Feb 16, 2006 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VUSION

See the table below for patents covering VUSION around the world.

Country Patent Number Title Estimated Expiration
Philippines 20480 SKIN CARE COMPOSITIONS See Plans and Pricing
Japan H0676330 See Plans and Pricing
Ireland 58380 Skin care compositions See Plans and Pricing
European Patent Office 0149561 SKIN CARE COMPOSITIONS See Plans and Pricing
Singapore 66489 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.